OS

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Retrieved on: 
Monday, February 5, 2024

The companies anticipate that the ODAC will review data related to the secondary endpoint of overall survival (OS) from the study.

Key Points: 
  • The companies anticipate that the ODAC will review data related to the secondary endpoint of overall survival (OS) from the study.
  • Final PFS data and interim OS data from the KarMMa-3 study were presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Abecma also received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for patients with triple-class exposed relapsed and refractory multiple myeloma after at least two prior therapies.
  • Regulatory applications for Abecma for this patient population remain under review with the EMA and Swissmedic.

Immutep Quarterly Activities Report Q2 FY24

Retrieved on: 
Tuesday, January 30, 2024

SYDNEY, AUSTRALIA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 December 2023 (Q2 FY24).

Key Points: 
  • Cash receipts from customers in Q2 FY24 were $38k, compared to $132k in Q1 FY24.
  • The net cash used in G&A activities in the quarter was $0.8 million, compared to $1.6 million in Q1 FY24.
  • The net cash used in R&D activities in the quarter was $6.9 million, compared to $9.7 million in Q1 FY24.
  • Total net cash outflows used in operating activities in the quarter were $5.5 million compared to $12.9 million in Q1 FY24.

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Friday, February 2, 2024

Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
  • If approved, tisotumab vedotin would be the first ADC granted European Union (EU) marketing authorization for people living with cervical cancer.
  • Data from the innovaTV 204 pivotal Phase 2 single-arm clinical trial evaluating TIVDAK as monotherapy in patients with previously treated recurrent or metastatic cervical cancer was also included in the MAA.
  • The safety profile of tisotumab vedotin in innovaTV 301 was consistent with its known safety profile as presented in the U.S. prescribing information.

Axis Products With AXIS OS 11 Now Support IEEE 802.1AE MACsec, Significantly Enhancing Security in Zero-Trust Networks

Retrieved on: 
Thursday, February 1, 2024

Axis becomes the first manufacturer of physical security products to support MACsec (Media Access Control Security), underscoring the company’s ongoing commitment to both device and data security.

Key Points: 
  • Axis becomes the first manufacturer of physical security products to support MACsec (Media Access Control Security), underscoring the company’s ongoing commitment to both device and data security.
  • Secure onboarding of an Axis device can be done through IEEE 802.1X EAP-TLS port-based network access control, in combination with an Axis device’s support for IEEE 802.1AR.
  • IEEE 802.1AR is part of the Axis Edge Vault cybersecurity platform and enables automatic authentication in an IEEE 802.1X network.
  • For more information on IEEE 802.1AE MACsec, please visit the Axis solutions page for enterprise IT or the AXIS OS knowledge base .

Atropos Health Leverages Google Cloud to Generate Actionable Clinical Evidence for Healthcare Institutions from Healthcare Data, Rapidly and Securely

Retrieved on: 
Tuesday, January 30, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240130637982/en/
    With Google Cloud and Atropos Health, health systems can spend less time maintaining infrastructure and more time leveraging insights from their data for improved operational efficiency and clinical decision making.
  • "Atropos Health is committed to enabling rapid real-world evidence with the highest levels of data privacy and security in healthcare.
  • Atropos Health's services facilitate secure access to real-world evidence, in compliance with regulations like HIPAA," said Dr. Brigham Hyde, CEO and co-founder of Atropos Health.
  • “We look forward to working with Atropos Health to drive impactful innovation and improve healthcare for everyone.”

Qubrid GPU Cloud Platform Early Access Available Immediately for Generative AI, LLM and Quantum Computing Simulations

Retrieved on: 
Tuesday, January 30, 2024

Qubrid, a leading GPU Cloud and Quantum Computing company announced immediate access to its leading hybrid GPU-QPU cloud computing platform focused at solving complex real-world problems.

Key Points: 
  • Qubrid, a leading GPU Cloud and Quantum Computing company announced immediate access to its leading hybrid GPU-QPU cloud computing platform focused at solving complex real-world problems.
  • The Qubrid Cloud Platform (QCP) shortens access to GPUs and QPUs making them accessible and programmable using an easy-to-use web interface.
  • The Qubrid platform is open now for developers, researchers and scientists to login and start working on AI/ML or Quantum Computing projects.
  • The platform is available for immediate login using below link:
    Pricing for on-demand GPUs and QPUs is available after logging in.

Aiden Doubles Staff and Clientele in 2023, Positioning Emerging Windows IT Automation Leader for Rapid Growth in 2024

Retrieved on: 
Thursday, February 1, 2024

MCKINNEY, Texas, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Aiden Technologies, the provider of modern, intelligent software packaging and deployment for Microsoft Windows, doubled its employees and customer base in 2023 while achieving 55% YoY ARR growth, three milestones in a year defined by sweeping advancements for the company. This significant momentum has further entrenched Aiden as a key leader in the exploding IT automation market and positions the company for another momentous year of growth in 2024.

Key Points: 
  • This significant momentum has further entrenched Aiden as a key leader in the exploding IT automation market and positions the company for another momentous year of growth in 2024.
  • "An organization would have to hire dozens of experts to complete the work that Aiden can accomplish in a matter of minutes.
  • In December, Aiden capped a year of extraordinary growth with the hiring of Cindy Heiner as CISO.
  • Meet Aiden Aiden is a leading provider of IT automation solutions, offering intelligent software packaging and deployment for Windows environments.

SMART Technologies to Unveil the Latest Interactive Display Family at TCEA 2024, Including the New RX Series - a Game-Changing Option for More Inclusive Learning

Retrieved on: 
Thursday, February 1, 2024

Leading the charge for EdTech innovation this year is SMART Technologies and the company's brand new and updated line of displays.

Key Points: 
  • Leading the charge for EdTech innovation this year is SMART Technologies and the company's brand new and updated line of displays.
  • From our revolutionary RX Series to the affordable GX Series, these interactive displays set a new standard for accessibility, engagement, and enduring value."
  • These new products help make class time higher quality time, each purpose-designed to enable more inclusive learning.
  • TCEA attendees can experience new SMART Technologies displays first-hand through interactive demos and presentations at booth 1122.

IGEL and Lenovo Announce Expanded Partnership; Lenovo Devices with Integrated IGEL OS License Now Available, Globally

Retrieved on: 
Thursday, February 1, 2024

SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- IGEL, provider of the secure endpoint OS for now and next, today announced an expanded partnership with Lenovo which accelerates the availability of Lenovo devices with integrated IGEL OS, worldwide. Through the expanded relationship, Lenovo ThinkPad L14 Gen 4 Intel and AMD notebooks and ThinkCentre Neo50q thin client and M75q tiny desktop are available with an integrated license of IGEL OS, available directly from Lenovo. This accelerates the availability of AI enhanced Lenovo devices operating with IGEL OS, and simplifies procurement for the secure, easy-to-manage endpoints, globally, through any Lenovo authorized channel.  

Key Points: 
  • Lenovo devices now offer a full IGEL OS license out-of-the-box, enhancing endpoint management, control, security and end-user experience
    SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- IGEL , provider of the secure endpoint OS for now and next, today announced an expanded partnership with Lenovo which accelerates the availability of Lenovo devices with integrated IGEL OS, worldwide.
  • This accelerates the availability of AI enhanced Lenovo devices operating with IGEL OS, and simplifies procurement for the secure, easy-to-manage endpoints, globally, through any Lenovo authorized channel.
  • "Our deepened partnership is a result of our extensive co-development efforts and will make the Lenovo devices, with integrated IGEL OS, easier to procure.
  • The Lenovo devices with integrated IGEL OS are available now from any Lenovo authorized channel.

BackBox Introduces Zero Trust Network Operations (ZTNO) to Automate Zero Trust Security for Network Operations

Retrieved on: 
Wednesday, January 31, 2024

DALLAS, Jan. 31, 2024 /PRNewswire/ -- In a significant stride towards enhancing network security, BackBox, a leader in security-centric automation for network teams, today introduces Zero Trust Network Operations (ZTNO). This groundbreaking offering is a best practice framework with six actionable pillars to automate cybersecurity considerations at the network layer for NetOps teams. To simplify ZTNO for network teams, BackBox has enhanced its Network Automation Platform with improved Privileged Access Manager, Network Vulnerability Management, and Search.

Key Points: 
  • BackBox Automation Platform for Network Teams announces improved Privileged Access Manager, Network Vulnerability Manager, and Search to simplify Zero Trust for NetOps
    DALLAS, Jan. 31, 2024 /PRNewswire/ -- In a significant stride towards enhancing network security, BackBox , a leader in security-centric automation for network teams, today introduces Zero Trust Network Operations (ZTNO).
  • To simplify ZTNO for network teams, BackBox has enhanced its Network Automation Platform with improved Privileged Access Manager, Network Vulnerability Management, and Search.
  • "BackBox's introduction of Zero Trust Network Operations (ZTNO) marks a significant advancement in network security, aligning NetOps with Zero Trust principles in a user-friendly, efficient, and comprehensive manner," said BackBox CEO Andrew Kahl.
  • For more information on BackBox Zero Trust Network Operations, go to https://backbox.com/ztno .